← Eichor
Study identifier: NCT06273176 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

Condition: Glioblastoma, IDH-wildtype · Glioblastoma · Glioblastoma Multiforme of Brain  ·  Sponsor: Erasmus Medical Center

PhaseN/A
Planned participants225
Who can joinAll sexes, N/A to 90 Years
Healthy volunteersNo

About this study

Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma. This study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Est…

This description comes directly from the study's public registry record.

Talk to the study team

Jasper Gerritsen, MD PhD  ·  +31107036130  ·  j.gerritsen@erasmusmc.nl

Arnaud Vincent, MD PhD  ·  +31107034211  ·  a.vincent@erasmusmc.nl

Always discuss trial participation with your own doctor first.

Locations (8)

University of California, San FranciscoSan Francisco, California, United StatesRecruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting
University Hospital LeuvenLeuven, BelgiumRecruiting
Universitätsklinikum HeidelbergHeidelberg, GermanyRecruiting
Technical University MunichMunich, GermanyNot Yet Recruiting
Erasmus Medical CenterRotterdam, South Holland, NetherlandsRecruiting
Haaglanden Medical CenterThe Hague, NetherlandsRecruiting
Inselspital Universitätsspital BernBern, SwitzerlandNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06273176